Active Filter(s):
Details:
Lundbeck gets options to re-acquire idalopirdine for predetermined undisclosed financial terms, with Denovo and Lundbeck sharing China rights in the event Lundbeck's options are exercised and Denovo retaining all global rights in the event Lundbeck's options are not exercised.
Lead Product(s): Idalopirdine
Therapeutic Area: Neurology Product Name: DB109
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Denovo Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 01, 2021